---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-162620"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2026-04-20T23:59:59+00:00"
generated_at: "2026-05-15T05:20:25.926080+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics presents preclinical data for PRT13722 KAT6A degrader at AACR 2026, plans IND mid-2026

## Summary
- PRT13722 is a first-in-class, orally bioavailable, potent and highly selective KAT6A degrader for HR+/HER2- breast cancer.
- Preclinical data show durable complete tumor regressions in xenograft models at well-tolerated doses as monotherapy.
- PRT13722 demonstrated improved preclinical hematological safety profile compared to prifetrastat.
- PRT13722 showed synergistic activity with endocrine therapy, CDK4/6 inhibitors, and PI3Kα inhibitors.
- IND filing expected in mid-2026; Phase 1 study initiation planned for second half of 2026.

## SEC filing metadata
- accession: 0001193125-26-162620
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2026-04-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000119312526162620/0001193125-26-162620-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000119312526162620/d135229d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-162620
- JSON: https://secwatch.observer/filing/0001193125-26-162620.json
- Plain text: https://secwatch.observer/filing/0001193125-26-162620.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.